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adequacy; second, if a measure of urea removal were to be
used, whether a simple urea reduction ratio is acceptable
or whether a measure that incorporates a normalizing
factor is necessary; and finally – whether the widespread
use of V as this normalizing factor is valid. Jenkins’
criticisms relate to the second point whereas our paper
addressed the third.
Focusing solely on normalized urea clearance presents a
flawed view of dialysis adequacy. There are many other
facets. Middle molecule removal is important. Reanalysis
of data from the HEMO study has demonstrated that
retention of b2 microglobulin was associated with in-
creased mortality.2 In addition to solute clearances, dialysis
prescription encompasses other goals, including sodium
and water, divalent ion and acid-base homeostasis. Dialysis
hypotension is more likely to occur when dialysis session
time is shortened, because of increased ultrafiltration rates,
and failure to achieve adequate sodium removal with
increased interdialytic weight gains.
Although we have criticized the appropriateness of the
use of Kt/V in prescribing hemodialysis, we do believe that
an assessment of the amount of dialysis delivered is vital,
unless very long and/or very frequent dialysis sessions
are employed. Normalized urea clearance, although not
perfect, is a useful marker of adequacy, though we believe
it could be used more astutely. Our paper proposes that the
normalizing factor should reflect metabolic activity, as use
of V may risk under-dialysis in women and small men. We
suggest that this should be borne in mind while we
continue to use Kt/V, and that the adequacy targets should
be adjusted in these two groups.
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To the Editor: We have read with interest the article by
Hai-Lu Zhao et al.1 on fat redistribution and adipocyte
transformation in uninephrectomized rats. Among numerous
interesting findings, the authors demonstrate increased
ectopic fat deposits in remnant kidneys and other solid
organs of chronic kidney disease animals. The authors
speculate on the possible mechanisms, taking into account
increased lipid production. This hypothesis is strengthened
by demonstrating that expression of HMG-CoA reductase,
the rate-limiting enzyme in cholesterologenesis pathway, is
increased in remnant kidneys.
We would like to confirm these results and highlight the
potential role of sterol regulatory element-binding proteins
(SREBPs) in the above-mentioned disturbances. SREBPs are
nuclear transcription factors that are currently regarded as
the major regulators of both cholesterologenesis and
lipogenesis.
We have shown that both gene expression and protein
abundance of SREBPs are increased in white adipose tissue2
and livers3 of chronic kidney disease rats. Moreover, increase
in SREBP expression has been demonstrated in kidneys of
diabetic mice4 and in experimental age-related nephropathy,5
where it has been clearly linked to lipid deposition in
glomeruli, and consequently to mesangial expansion, glo-
merulosclerosis, and proteinuria.
These results complement the findings demonstrated by
Zhao et al. as they bring us closer to elucidating the issue of
altered lipid metabolism in the course of chronic kidney
disease.3
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proteins (SREBPs) in the development of fat redistribution
and adipocyte transformation associated with unine-
phrectomy-induced chronic renal impairment.1 SREBPs
are membrane-bound transcription factors that regulate
multiple genes involved in cholesterol biosynthesis and
uptake.2 In our ongoing studies, we aim to define the
correlations between SREBPs and fat dysfunction con-
comitant with the course of chronic kidney disease in
uninephrectomized rats. Chmielewski et al. have demon-
strated an increased gene expression and protein abun-
dance of SREBPs in white adipose tissue3 and livers4 of 5/6
nephrectomized rats. Although these cross-sectional re-
sults complement our findings of fat dysfunction in
uninephrectomized rats,1 one has to be cautious in
interpreting data from different nephrectomized experi-
mental models. Renal failure model set up by 2/3, 5/6, or
7/8 nephrectomy might be different from the chronic
kidney impairment induced by uninephrectomy in our
study.1 For example, our study demonstrated that the
protein abundance of HMG-CoA reductase in the liver was
similar among the three groups of rats with different lipid
profiles.1 As stated in our paper,1 ‘nephrectomy is a severe
procedure that produces a myriad of effects on many
systems, including the renin–angiotensin–aldosterone sys-
tems and the endocrine organs’. Indeed, the uninephrecto-
mized rats also showed pancreatic b-cell deficit, insulin
deficiency, and glucose intolerance.5 All these data
demonstrate that the kidney is one of the most important
homeostatic organs.
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To the Editor: A recent article demonstrated that 8-week
paricalcitol treatment of 5/6 nephrectomized rats suppressed
expression of several genes of the renin-angiotensin system
(RAS) in the kidney at the mRNA level.1 We recently
performed a similar study,2 and have now determined
the RAS components from the kidneys with very different
results.
In our experiment, rats were put on a 12-week paricalcitol
(200 ng/kg) treatment period 15 weeks after 5/6 nephrectomy
(NX). After 27 weeks of renal insufficiency, the mRNA values
of almost all RAS components and connective tissue growth
factor were different from sham-operated rats. However, no
suppression of RAS genes between untreated and paricalcitol-
treated NX rats was observed at the mRNA level (Table 1). In
the study by Freundlich et al.,1 the NX rats were put on
paricalcitol (100 or 300 ng/kg) already 4 days after surgery.
The subtotal NX produces a shock that undoubtedly alters
gene expression in the remnant kidney, and it seems likely
that these processes have not yet stabilized in 4 days. In our
Table 1 | No differences in RAS components between untreated and paricalcitol-treated NX rats (200 ng/kg thrice weekly)
Sham (n=12) NX (n=7) NX+Paricalcitol (n=8)
Kidney mRNA using RT–PCR
AT1a receptor ( 104/ng total RNA) 0.99±0.04 0.83±0.08* 0.80±0.05*
AT2 receptor ( 102/ng total RNA) 0.76±0.15 0.32±0.06* 0.19±0.03*
AT4 receptor ( 103/ng total RNA) 2.99±0.21 3.76±0.28* 3.90±0.24*
Renin receptor ( 104/ng total RNA) 2.31±0.15 1.77±0.11* 1.74±0.08*
MAS oncogene ( 102/ng total RNA) 4.80±0.34 4.92±0.48 4.77±0.41
ACE ( 104/ng total RNA) 0.98±0.68 1.72±0.21* 2.06±0.20*
ACE2 ( 104/ng total RNA) 1.10±0.08 0.65±0.14* 0.49±0.09*
CTGF ( 104/ng total RNA) 1.74±0.11 2.76±0.49* 2.84±0.19*
Plasma renin activity (ng/ml/h) 24.3±3.0 1.7±1.0* 1.4±0.7*
ACE, angiotensin-converting enzyme; CTGF, connective tissue growth factor; NX, 5/6 nephrectomy; RT–PCR, reverse transcription–polymerase chain reaction.
5/6 nephrectomy at the age of 8 weeks (study week 0), disease progression period 0–15 weeks, treatment period 15–27 weeks (12 weeks). Mean±s.e.m., *Po0.05 compared
with the sham group.
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